J&J’s new part­ner­ship with Elek­trofi; Enyo rais­es €39M; Ar­row­head­'s $450M of­fer­ing

Plus, news about TC Bio­Pharm, Bio­Cen­triq, 4D Mol­e­c­u­lar and Ar­bor Biotech­nolo­gies, and Long­board Phar­ma­ceu­ti­cals:

John­son & John­son teams up with Elek­trofi: The Boston biotech will work with J&J’s Janssen Biotech to cre­ate an at-home self-ad­min­is­tered un­der-the-skin ver­sion of a “lead on­col­o­gy as­set.” Elek­trofi snagged an up­front pay­ment of $18 mil­lion and could re­ceive $155 mil­lion or more in mile­stones per tar­get in the mul­ti-tar­get pact. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER